

Amendment to the specification:

Insert the paper copy of the Sequence Listing filed herewith following the Drawings.

*Please amend the priority claim in the first paragraph at page 1, and amended by a Preliminary Amendment filed March 4, 2002, as follows:*

This application is a divisional of U.S. Application No. 09/373,432, filed August 13, 1999, now U.S. Patent No. 6,459,996, which claims priority to U.S. Provisional Application No. 60/096,452, filed August 13, 1998, and U.S. Patent Application No.: 09/373,432 filed on August 13, 1999, allowed. The contents of all the aforementioned applications are hereby incorporated by reference.

*Please amend the paragraph beginning at page 7, which starts with "Figure 4: Quanta was ... ", as follows:*

Figure 4: Quanta was used to superimpose *E. coli* UDP-galactose 4 epimerase (GalE) (SEQ ID NO:1) and *E. coli* GDP-fucose synthetase (coli.GFS) (SEQ ID NO:2) as shown in figure 3. The two sequences were then aligned based upon the structural alignment and the human GDP-fucose synthetase (human.GFS) amino acid sequence (SEQ ID NO:3) was aligned to this pair. Identical residues are boxed in red, homologous in grey, and residues shared between two of the three proteins are boxed in blue.